SCYNEXIS (STU:135) Total Equity: €35.73 Mil (As of Mar. 2026)


STU:135 SCYNEXIS Inc STU:135
43 GF Score
Price €4.84
GF Value €19.77
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is SCYNEXIS Total Equity?

SCYNEXIS STU:135 43 Total Equity is €35.73 Mil as of Mar. 2026. GuruFocus rates STU:135 with a GF Score™ of 43/100 and a GF Value™ of €19.77 (Possible Value Trap). The stock has 4 warning signs investors should review.

SCYNEXIS's total equity for the quarter that ended in Mar. 2026 was €35.73 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SCYNEXIS Total Equity Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Total Equity Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.51 3.05 66.91 52.60 42.17

SCYNEXIS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.74 38.55 31.04 42.17 35.73
STU:135
43GF Score
SCYNEXIS Inc STU:135
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SCYNEXIS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=50.409-8.242
=42.17

SCYNEXIS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=67.146-31.416
=35.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €35.73 Mil mean?
SCYNEXIS (STU:135) has a Total Equity of €35.73 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for SCYNEXIS and its competitors.
Is SCYNEXIS's Total Equity too high?
SCYNEXIS's current Total Equity is €35.73 Mil. Overall, SCYNEXIS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Total Equity compare to ETST and BGM?
SCYNEXIS's Total Equity of €35.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for SCYNEXIS and its competitors. SCYNEXIS's current Total Equity is €35.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €19.77, compared to a current price of €4.84 — trading 75.5% below its estimated fair value. The current Total Equity is €35.73 Mil. SCYNEXIS's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Total Equity is €35.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (STU:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.84 is trading 75.5% below its estimated GF Value™ of €19.77. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for STU:135:

  • Total Equity: €35.73 Mil
  • GF Value™: €19.77 vs. price of €4.84 (75.5% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score

Get the complete analysis for STU:135

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.84
Price
€19.77
GF Value